BAUSCH + LOMB INFUSE contact lenses feature a next generation contact lens material (kalifilcon A), which is designed to meet the unmet needs of contact lens wearers, including those who experience contact lens dryness

FDA device

The US FDA’s Center for Devices and Radiological Health. (Credit: The U.S. Food and Drug Administration)

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for BAUSCH + LOMB INFUSE™ daily disposable silicone hydrogel (SiHy daily) contact lenses.

BAUSCH + LOMB INFUSE contact lenses feature a next generation contact lens material (kalifilcon A), which is designed to meet the unmet needs of contact lens wearers, including those who experience contact lens dryness. Engineered with Bausch + Lomb’s most advanced proprietary contact lens technologies, BAUSCH + LOMB INFUSE offers outstanding breathability for healthy lens wear while providing exceptional all-day comfort and high definition optics.

“Bausch + Lomb continues to push the innovation curve in the contact lens space with the FDA’s clearance of BAUSCH + LOMB INFUSE,” said Joe Gordon, U.S. president, Bausch + Lomb. “We are excited to add this breakthrough new SiHy daily contact lens to our portfolio and provide the outstanding health, vision and comfort that practitioners expect and patients deserve from Bausch + Lomb. We anticipate BAUSCH + LOMB INFUSE will be available to eye care practitioners in the second half of 2020.”

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.

Source: Company Press Release